Structure Therapeutics
GPCR
Market cap $2.22B

38.82 USD

-0.68

1.72%

At close Oct 21, 4:00 PM EDT

After hours

38.82

+0.00

0.00%

1 day

-1.72%

5 days

6.74%

1 month

-8.34%

3 months

6.09%

6 months

7.77%

Year to date

-3.89%

1 year

-42.51%

5 years

49.31%

About: Structure Therapeutics Inc is a clinical-stage biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.

Employees: 136

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 7 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

336% more first-time investments, than exits

New positions opened: 61 | Existing positions closed: 14

183% more call options, than puts

Call options by funds: $71M | Put options by funds: $25.1M

91% more repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 33

39% more funds holding

Funds holding: 119 [Q1] → 166 (+47) [Q2]

26% more capital invested

Capital invested by funds: $1.88B [Q1] → $2.37B (+$496M) [Q2]

3.86% more ownership

Funds ownership: 31.43% [Q1] → 35.28% (+3.86%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 4 [Q1] → 4 (+0) [Q2]

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$65

67%

upside

Avg. target

$76

95%

upside

High target

$118

204%

upside

7 analyst ratings

7 positive

100%

0 neutral

0%

0 negative

0%

Cantor Fitzgerald Prakhar Agrawal 41% 1-year accuracy 9 / 22 met price target	67%upside $65	Overweight Reiterated	23 Sept 2024
Morgan Stanley Terence Flynn 70% 1-year accuracy 14 / 20 met price target	204%upside $118	Overweight Initiated	23 Sept 2024
Cantor Fitzgerald Prakhar Agrawal 41% 1-year accuracy 9 / 22 met price target	67%upside $65	Overweight Reiterated	16 Sept 2024
Cantor Fitzgerald Prakhar Agrawal 41% 1-year accuracy 9 / 22 met price target	67%upside $65	Overweight Reiterated	9 Sept 2024
Cantor Fitzgerald Prakhar Agrawal 41% 1-year accuracy 9 / 22 met price target	67%upside $65	Overweight Reiterated	19 Aug 2024

See Analyst Rankings

Financial journalist opinion

Zacks Investment Research

Does Structure Therapeutics Inc. Sponsored ADR (GPCR) Have the Potential to Rally 115.8% as Wall Street Analysts Expect?

The consensus price target hints at an 115.8% upside potential for Structure Therapeutics Inc. Sponsored ADR (GPCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does Structure Therapeutics Inc. Sponsored ADR (GPCR) Have the Potential to Rally 115.8% as Wall Street Analysts Expect?

Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D.

SAN FRANCISCO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced key leadership appointments to drive its next phase of development and operational success. Blai Coll, M.D., Ph.D., has been promoted to Chief Medical Officer, replacing Mark Bach, M.D., Ph.D. as part of a planned succession, effective September 18. Dr. Coll has served as Vice President of Clinical Development at Structure since 2022, leading the GSBR-1290 program, Structure's oral small molecule GLP-1 agonist that is planned to enter Phase 2b clinical development for obesity in the fourth quarter of 2024. In addition, Ashley Hall, J.D., has been appointed to the newly created position of Chief Development Officer, and will be responsible for clinical development operations, project management, regulatory affairs and quality assurance.

Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D.

24/7 Wall Street

Five Top Obesity Stocks to Buy and Hold Long Term

Karl-Hendrik Tittel / Getty Images There's also Altimmune (NASDAQ:ALT), whose pemvidutide treatment led to weight loss while preserving lean mass.

Five Top Obesity Stocks to Buy and Hold Long Term

Structure Therapeutics Appoints Angus C. Russell to Board of Directors

Former Shire CEO brings more than 30 years of experience in building and scaling companies in the global biopharmaceutical industry Former Shire CEO brings more than 30 years of experience in building and scaling companies in the global biopharmaceutical industry

Structure Therapeutics Appoints Angus C. Russell to Board of Directors

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

SAN FRANCISCO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced management will participate at the following investor conferences in September:

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

While Eli Lilly & Co. and Novo Nordisk dominate the obesity-drug market, there's a vast field of would-be competitors closing in behind them — and the most successful among those next-wave contenders stand to capture up to 20% of the lucrative market, Jefferies analysts said in a research note Monday.

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

Structure Therapeutics: Pay Attention To This Overlooked Player In GLP-1 Weight Loss Field

GLP-1 agonist drugs like Novo Nordisk's semaglutide and Eli Lilly's tirzepatide are set to become all-time best-selling drugs. Structure Therapeutics has entered the race with an oral GLP-1 candidate, GSBR-1290, showing promising weight loss results and a strong safety profile. Despite competition in the field, Structure's progress and diverse pipeline of candidates make it a potentially strong investment opportunity.

Structure Therapeutics: Pay Attention To This Overlooked Player In GLP-1 Weight Loss Field

3 Promising Biotech Stocks for the Long-Term: August 2024

Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Look at Eli Lilly (NYSE: LLY ), for example.

3 Promising Biotech Stocks for the Long-Term: August 2024

Zacks Investment Research

What's in Store for Structure Therapeutics (GPCR) in Q2 Earnings?

Structure Therapeutics (GPCR) is expected to provide updates on the developmental pathway of its lead product candidate, GSBR-1290, for diabetes and obesity indications in the Q2 earnings release.

What's in Store for Structure Therapeutics (GPCR) in Q2 Earnings?

The Motley Fool

Missed Out on Eli Lilly? These 2 Healthcare Stocks Have Big Catalysts on the Horizon.

Eli Lilly is having great success in the market for weight loss treatments. Viking is working on a candidate that could potentially outperform Eli Lilly's.

Missed Out on Eli Lilly? These 2 Healthcare Stocks Have Big Catalysts on the Horizon.

See News Rankings

Charts implemented using Lightweight Charts™